{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:59:13Z","timestamp":1794002353801,"version":"4.8.0"},"reference-count":28,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Advanced solid organ tumors, particularly breast, lung, and prostate cancers, frequently metastasize to bone, leading to debilitating skeletal-related events (SREs). Denosumab, a RANKL inhibitor, is crucial in preventing SREs. This study aimed to comparatively evaluate the efficacy and adverse effect profiles of denosumab in patients with bone metastases originating from these three common cancer types. Materials and Methods: This retrospective study included 146 patients treated with denosumab for bone metastases. Data on demographics, SREs before and during denosumab treatment, serum creatinine, calcium, and magnesium levels (at baseline, 3, and 6 months), other adverse effects, and survival were analyzed. Results: Before denosumab, SREs were present in 36.3% of patients (breast: 43.4%, prostate: 28%, lung: 33.8%). During denosumab treatment, SRE rates markedly decreased across all groups (breast: 9.4%, prostate: 16.0%, lung: 8.8%), with no significant intergroup difference in on-treatment SREs. Significant decreases in serum calcium levels were observed at 3 and 6 months post-denosumab initiation in breast (p &lt; 0.0001) and lung cancer patients (p = 0.001). Mean creatinine levels significantly decreased in lung (p &lt; 0.0001) and prostate (p = 0.020) cancer patients at 3 and 6 months. Overall survival significantly differed, with lung cancer patients having the shortest median survival (p &lt; 0.005). Conclusions: Denosumab effectively reduces the incidence of SREs in patients with bone metastases from breast, lung, and prostate cancer. However, clinicians must diligently monitor for hypocalcemia, a notable adverse effect, particularly at 3 and 6 months after starting denosumab, with specific caution warranted in patients with lung cancer.<\/jats:p>","DOI":"10.3390\/medicina61091637","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T09:32:01Z","timestamp":1757496721000},"page":"1637","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Managing Bone Metastases with Denosumab: Real-World Data and Critical Monitoring Points in Breast, Lung, and Prostate Cancers"],"prefix":"10.3390","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8217-3471","authenticated-orcid":false,"given":"Sibel","family":"Oyucu Orhan","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Bursa City Hospital, Bursa 16250, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3970-2344","authenticated-orcid":false,"given":"Bedrettin","family":"Orhan","sequence":"additional","affiliation":[{"name":"Department of Hematology, Bursa Yuksek Ihtisas Training and Research Hospital, University of Health Science, Bursa 16000, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7491-8058","authenticated-orcid":false,"given":"\u015eeyma","family":"Esenbu\u011fa","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, Bursa Uludag University, Bursa 16059, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8575-5477","authenticated-orcid":false,"given":"Seda","family":"Sali","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Bursa City Hospital, Bursa 16250, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1591-3323","authenticated-orcid":false,"given":"Burcu","family":"Caner","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ayd\u0131n Atat\u00fcrk Public Hospital, Aydin 09020, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7537-1699","authenticated-orcid":false,"given":"Birol","family":"Ocak","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Bursa Yuksek Ihtisas Training and Research Hospital, University of Health Science, Bursa 16000, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7846-0870","authenticated-orcid":false,"given":"Ahmet Bilgehan","family":"\u015eahin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Bursa Uludag University, Bursa 16059, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3669-6391","authenticated-orcid":false,"given":"Adem","family":"Delig\u00f6n\u00fcl","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Bursa Uludag University, Bursa 16059, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9732-5340","authenticated-orcid":false,"given":"T\u00fcrkkan","family":"Evrensel","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Bursa Uludag University, Bursa 16059, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0070-0889","authenticated-orcid":false,"given":"Erdem","family":"\u00c7ubuk\u00e7u","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Bursa Uludag University, Bursa 16059, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.critrevonc.2017.04.008","article-title":"Systematic review and meta-analysis on the proportion of patients with breast cancer who develop bone metastases","volume":"115","author":"Body","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3892\/or.2025.8879","article-title":"Bone metastases of prostate cancer: Molecular mechanisms, targeted diagnosis and targeted therapy (Review)","volume":"53","author":"Guo","year":"2025","journal-title":"Oncol. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Long, N., Woodlock, D., D\u2019Agostino, R., Nguyen, G., Gangai, N., Sevilimedu, V., and Do, R.K.G. (2025). Incidence and Prevalence of Bone Metastases in Different Solid Tumors Determined by Natural Language Processing of CT Reports. Cancers, 17.","DOI":"10.3390\/cancers17020218"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials","volume":"48","author":"Lipton","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1586\/era.11.204","article-title":"Denosumab for the management of bone disease in patients with solid tumors","volume":"12","author":"Body","year":"2012","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: Integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","volume":"23","author":"Saad","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/SPC.0000000000000749","article-title":"Assessment of the benefits of bone modifying agents in the management of advanced breast, prostate, and lung cancers","volume":"19","author":"Leigh","year":"2025","journal-title":"Curr. Opin. Support. Palliat. Care"},{"key":"ref_11","unstructured":"(2025, June 05). Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0: National Institutes of Health, National Cancer Institute, Available online: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.2217\/fon-2022-0098","article-title":"Long-term safety and efficacy of bisphosphonate therapy in advanced lung cancer with bone metastasis","volume":"18","author":"Wei","year":"2022","journal-title":"Future Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.cllc.2015.06.004","article-title":"Therapeutic Potential of Denosumab in Patients With Lung Cancer: Beyond Prevention of Skeletal Complications","volume":"16","author":"Garrido","year":"2015","journal-title":"Clin. Lung Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Wong, S.K., Mohamad, N.V., Giaze, T.R., Chin, K.Y., Mohamed, N., and Ima-Nirwana, S. (2019). Prostate Cancer and Bone Metastases: The Underlying Mechanisms. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20102587"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Nakamura, K., Kaya, M., Yanagisawa, Y., Yamamoto, K., Takayashiki, N., Ukita, H., Nagura, M., Sugiue, K., Kitajima, M., and Hirano, K. (2024). Denosumab-induced hypocalcemia in patients with solid tumors and renal dysfunction: A multicenter, retrospective, observational study. BMC Cancer, 24.","DOI":"10.1186\/s12885-024-11942-2"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Mizuta, K., Oshiro, H., Katsuki, R., Tsuha, Y., Aoki, Y., Tome, Y., and Nishida, K. (2023). Denosumab administration for bone metastases from solid tumors: A retrospective cross-sectional study. BMC Cancer, 23.","DOI":"10.1186\/s12885-023-11495-w"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"EVIDoa2200162","DOI":"10.1056\/EVIDoa2200162","article-title":"Long-Term Outcomes of Adjuvant Denosumab in Breast Cancer","volume":"1","author":"Gnant","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_18","first-page":"679","article-title":"Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: An analysis of data from patients with solid tumors","volume":"22","author":"Henry","year":"2014","journal-title":"Support. Care Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"100416","DOI":"10.1016\/j.jbo.2022.100416","article-title":"Experience with denosumab (XGEVA\u00ae) for prevention of skeletal-related events in the 10 years after approval","volume":"33","author":"Cadieux","year":"2022","journal-title":"J. Bone Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ctrv.2012.07.002","article-title":"Denosumab in patients with cancer and skeletal metastases: A systematic review and meta-analysis","volume":"39","author":"Peddi","year":"2013","journal-title":"Cancer Treat. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1038\/s41416-018-0225-4","article-title":"Denosumab and breast cancer risk in postmenopausal women: A population-based cohort study","volume":"119","author":"Giannakeas","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1016\/j.ejca.2015.05.016","article-title":"Hypocalcaemia in patients with metastatic bone disease treated with denosumab","volume":"51","author":"Body","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2008.19.2146","article-title":"Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates","volume":"27","author":"Fizazi","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/cen.14169","article-title":"Hypocalcaemia following denosumab in prostate cancer: A clinical review","volume":"92","author":"Lau","year":"2020","journal-title":"Clin. Endocrinol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1097\/JTO.0b013e31826aec2b","article-title":"Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: Subgroup analysis from a randomized phase 3 study","volume":"7","author":"Scagliotti","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.2169\/internalmedicine.8908-17","article-title":"Prolonged Hypocalcemia Following a Single Dose of Denosumab for Diffuse Bone Metastasis of Gastric Cancer after Total Gastrectomy","volume":"56","author":"Iizumi","year":"2017","journal-title":"Intern. Med."},{"key":"ref_27","first-page":"102183","article-title":"Severe denosumab-induced hypocalcemia requiring long-term intensified medication in a patient with EGFR-mutant lung cancer and diffuse osteoblastic bone metastases","volume":"54","author":"Mori","year":"2025","journal-title":"Respir. Med. Case Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1200\/JCO.2012.47.1102","article-title":"PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer","volume":"31","author":"Dediu","year":"2013","journal-title":"J. Clin. Oncol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/9\/1637\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:43:04Z","timestamp":1760035384000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/9\/1637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,10]]},"references-count":28,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["medicina61091637"],"URL":"https:\/\/doi.org\/10.3390\/medicina61091637","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,10]]}}}